Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

• Status: Completed
• Trial end date: 2009-05-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Treatments: Maribavir

Criteria

Inclusion Criteria:

• Allogeneic stem cell transplant recipient

• Recipient or donor CMV seropositive

• Have transplant engraftment

• Able to swallow tablets

Exclusion Criteria:

• CMV organ disease

• HIV infection

• Use of other anti-CMV therapy post-transplant